 Randomized patient-blind placebo controlled study. Hb level of 10 gdl will be used as a cut-off value for our study based on the guidelines published by American Society of Clinical Oncology and the American Society of Hematology for the treatment of cancer-related anemia, recommending Hb10 gdl as a treatment threshold. 